TD Cowen Reiterates Buy Rating on Supernus Pharmaceuticals (SUPN)
Tweet Send to a Friend
TD Cowen analyst Stacy Ku, Ph.D. reiterated a Buy rating and $43.00 price target on Supernus Pharmaceuticals (NASDAQ: SUPN).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
